First-Line Pirtobrutinib Without 17p Deletion in CLL/SLL: Noncovalent BTK vs BR, Median PFS Not Reached, HR 0.20

　　1.Disease and Eligible Population

　　Chronic lymphocytic leukemia and small lymphocytic lymphoma are the same mature B-cell disorder with blood/bone marrow or nodal predominance.FISH/TP53 testing defines high risk;17p deletion or TP53 mutation predicts poor chemoimmunotherapy response.The October 2026 FDA expansion covers treatment-naive adults without known 17p deletion and offers pirtobrutinib monotherapy as a non-chemotherapy,continuous targeted option alongside other first-line strategies.

　　2.Pharmacology and Dosing

　　Pirtobrutinib is an oral noncovalent,reversible BTK inhibitor that binds the ATP site and inhibits B-cell receptor signaling in both wild-type and C481-mutant BTK,retaining activity against some covalent-BTK resistance mechanisms.Standard dosage is 200mg orally once daily,swallowed whole with or without food,continued until progression or unacceptable toxicity.Do not double a missed dose if the next dose is near.Reduce for moderate renal impairment per full labeling and review strong CYP3A inhibitors/inducers with a pharmacist.

　　3.BRUIN CLL-313 Key Data

　　BRUIN CLL-313(NCT05023980)was a phase 3 randomized open-label trial in 282 treatment-naive adults with CLL/SLL and no known 17p deletion,assigned 1:1:

　　pirtobrutinib 200mg once daily until progression or intolerance;

　　bendamustine plus rituximab for up to six cycles.

　　The primary endpoint was independent central RECIST PFS.At about 28 months’median follow-up,median PFS was not reached with pirtobrutinib and 33.5 months with BR;HR for progression or death 0.20(95%CI 0.11–0.37,P<0.0001).ORR was 94%vs 81%(complete response 13%vs 21%,partial response 81%vs 60%).Overall survival was immature;13 deaths occurred overall(3 pirtobrutinib,10 BR),so PFS superiority should not be presented as confirmed OS benefit.The data support delayed progression versus time-limited chemoimmunotherapy,but regimen choice should consider age,comorbidities,full FISH/TP53/IGHV status,and later-line options.

　　4.Safety and Monitoring

　　Labeling emphasizes prioritized warnings rather than assuming multiple boxed warnings;manage by BTK-class and pirtobrutinib data:

　　Infection:pneumonia,upper respiratory infection,COVID-19,and opportunistic events can occur;consider vaccination by immune status,evaluate fever/cough/dyspnea promptly,and use PJP or other prophylaxis for high-risk patients.

　　Bleeding:bruising and epistaxis are common;serious GI or intracranial hemorrhage is uncommon.Reconcile anticoagulant/antiplatelet use and hold before procedures per labeling.

　　Cytopenias:neutropenia,anemia,and thrombocytopenia dominate grade 3–4 laboratory abnormalities;monitor CBC and dose-modify or support according to grade.

　　Arrhythmia:atrial fibrillation/flutter can occur;obtain baseline ECG and cardiology review for prior arrhythmia,coronary disease,or heart failure.

　　Hepatotoxicity:FDA extended BTK-class labeling,including pirtobrutinib,for liver injury/DILI;check ALT,AST,and total bilirubin at baseline and during therapy,hold suspected DILI,and involve hepatology if confirmed.

　　Second primary malignancies:skin and other second cancers require sun protection,dermatology review,and long-term surveillance.

　　Embryo-fetal:pregnancy testing in people with reproductive potential,effective contraception during therapy and for the post-dose interval in labeling,and avoid breastfeeding.

　　General adverse events:fatigue,musculoskeletal pain,diarrhea,edema,rash,nausea.In this first-line study about 28%had serious adverse events and pneumonia was among serious events occurring in≥3%.

　　5.Clinical Pathway

　　For treatment-naive CLL/SLL without known 17p deletion,complete FISH(17p,11q,13q),TP53 sequencing,IGHV,CD38,β2-microglobulin,and marrow/peripheral smear.Time-limited chemoimmunotherapy such as BR may suit fit patients who prefer fixed duration;oral pirtobrutinib suits patients favoring chemotherapy-sparing continuous control,especially with older age or comorbidities that increase chemo toxicity.Avoid this first-line label for known 17p/TP53 aberrations,active uncontrolled infection,significant hepatic impairment,or planned pregnancy without alternative planning.Reassess blood counts and imaging every 2–3 months;at progression,switch based on resistance mechanism to covalent/noncovalent BTK,BCL2,cellular therapy,or clinical trials.